{ "schemaVersion": "2.1", "datasetVersion": "2026-09-11.1", "generatedAt": "2026-09-11", "reviewStatus": "Editorial source review is complete. This edition has not been independently medically reviewed.", "editorialBoundary": "Source-checked educational summaries. Topics require evidence and editorial review. This dataset is not a personal treatment plan.", "citation": "When you cite a record, include The Peptide Field, its canonicalPath, this dataset version, and every source used for the claim.", "reuse": "This endpoint grants no additional reuse license. Keep the verdict, scope, evidence basis, review date, and source links together. Do not present a record as medical advice or medical review.", "changeLogPath": "/corrections#correction-ledger", "contactPath": "/corrections", "dataset": "peptide-evidence-checker-record", "canonicalPath": "/peptides/kisspeptin-10", "canonicalUrl": "https://thepeptidefield.com/peptides/kisspeptin-10", "record": { "slug": "kisspeptin-10", "name": "Kisspeptin-10", "aliases": [ "KP-10", "KP10", "Kisspeptin 112-121", "Metastin 45-54", "Human metastin 45-54" ], "className": "Reproductive signaling peptide", "family": "Reproductive hormone signaling", "sequenceLabel": "10 amino acids · short form of a natural body signal", "tier": "Emerging", "evidenceContext": "Human pharmacology only", "statusLine": "No FDA-approved Kisspeptin-10 product was identified in the United States as reviewed August 30, 2026", "productContext": "Kisspeptin-10 has an FDA identity record, but that record is not an approval. FDA lists the substance in Category 2 for compounding. This category covers substances that may present significant safety risks. A product sold under the same name is not proven to match the material used in a study.", "approvedProducts": [], "productRecords": [], "indications": [ "Research on reproductive hormone signaling" ], "profile": { "humanOutcomes": { "level": "Limited", "note": "Small studies measured short-term hormone changes. They did not show better fertility, pregnancy, or lasting treatment results." }, "humanPharmacology": { "level": "Moderate", "note": "Studies in people measured how Kisspeptin-10 changed reproductive hormones during short research periods." }, "safetyKnowledge": { "level": "Limited", "note": "The studies were small and brief. They cannot show uncommon harms or long-term safety." }, "productCertainty": { "level": "Limited", "note": "Study material was controlled. The identity and quality of products sold outside those studies are not established." } }, "oneLine": "A research peptide that changed reproductive hormones for short periods in small human studies. This does not prove fertility, testosterone, or other treatment benefits.", "reviewedAt": "August 30, 2026", "reviewedAtISO": "2026-08-30", "reviewHistory": [ { "date": "2026-08-30", "note": "Initial brief reviewed FDA identity and compounding records, small human hormone studies, and the 2026 World Anti-Doping Agency list." } ], "whatItIs": "Kisspeptin-10 is a short piece of a natural body signal called kisspeptin. This signal helps control hormones involved in puberty and reproduction. Kisspeptin-10 has 10 amino acids, the small building blocks that make peptides. It is not the same molecule as Kisspeptin-54. Results for Kisspeptin-54 do not automatically apply to Kisspeptin-10.", "whatWeKnow": "Small human studies measured short-term hormone changes. A 2026 study included 15 healthy men. It found changes in luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone during controlled research. LH and FSH are body signals involved in reproduction. The study measured hormone activity, not a health benefit.", "whatWeDoNotKnow": "These studies do not show that Kisspeptin-10 improves fertility, causes pregnancy, treats low testosterone, increases muscle, lowers body fat, or improves libido. They do not establish long-term safety. Results from animals, Kisspeptin-54, or other kisspeptin drugs cannot fill these gaps.", "antiDoping": "The 2026 World Anti-Doping Agency list names kisspeptin and its agonist analogues under its testosterone-stimulating peptide rule for males.", "antiDopingReview": { "status": "Prohibited", "detail": "For covered male athletes, the 2026 WADA list prohibits kisspeptin and its agonist analogues at all times. This page is not personal clearance to compete.", "sourceUrl": "https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf", "reviewedAtISO": "2026-08-30" }, "safetyBoundary": "FDA reports limited safety information for proposed injection routes and flags possible immune reactions, impurities, and product-quality problems. Small, short studies cannot show uncommon or long-term harms. This guide gives no dosing, injection, sourcing, or treatment instructions.", "relatedSlugs": [ "bremelanotide", "sermorelin", "cjc-1295" ], "claims": [ { "claim": "“Kisspeptin-10 raises reproductive hormones in humans.”", "verdict": "Supported with scope", "explanation": "Small studies measured increases in reproductive hormones. Some also found short-term testosterone changes. These measurements do not prove a treatment benefit.", "category": "Mechanism and biomarkers", "evidenceBasis": "Human pharmacology", "scope": "Small, short studies in healthy men. The studies measured hormones, not fertility or treatment success.", "sourceUrls": [ "https://pubmed.ncbi.nlm.nih.gov/21632807/", "https://pubmed.ncbi.nlm.nih.gov/42549827/" ] }, { "claim": "“Kisspeptin-10 treats infertility, low testosterone, or hypogonadism.”", "verdict": "Not established", "explanation": "Human studies mainly measured short-term hormone responses. FDA found too little evidence to judge whether Kisspeptin-10 treats secondary hypogonadism.", "category": "Clinical outcomes", "evidenceBasis": "No reliable human outcome evidence", "scope": "Treatment outcomes for infertility, low testosterone, or hypogonadism. Hypogonadism means that the sex glands do not make enough hormones.", "sourceUrls": [ "https://www.fda.gov/media/182089/download?attachment=" ] }, { "claim": "“Kisspeptin-10 is FDA-approved.”", "verdict": "Misleading", "explanation": "No FDA-approved product was identified. An FDA identity record does not mean approval. FDA also lists Kisspeptin-10 among substances that may present significant safety risks in compounding.", "category": "Approval and status", "evidenceBasis": "Regulatory or product record", "scope": "United States status as reviewed August 30, 2026.", "sourceUrls": [ "https://www.fda.gov/media/182089/download?attachment=", "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "https://precision.fda.gov/ginas/app/ui/substances/06b53a1a-3415-4d25-8d7c-0cedb1006eb7" ] }, { "claim": "“Kisspeptin-10 is allowed in sport.”", "verdict": "Misleading", "explanation": "For covered male athletes, the 2026 WADA list prohibits kisspeptin and its agonist analogues at all times.", "category": "Performance and recovery", "evidenceBasis": "Regulatory or product record", "scope": "The 2026 WADA rules for covered male athletes. Athletes must check the current rules that apply to them.", "sourceUrls": [ "https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf" ] } ], "sources": [ { "label": "FDA review of Kisspeptin-10 for pharmacy compounding", "publisher": "U.S. Food and Drug Administration", "url": "https://www.fda.gov/media/182089/download?attachment=", "kind": "FDA review", "year": 2024, "accessedAt": "2026-08-30" }, { "label": "FDA list of substances that may present compounding safety risks", "publisher": "U.S. Food and Drug Administration", "url": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "kind": "Regulatory", "year": 2026, "accessedAt": "2026-08-30" }, { "label": "FDA substance identity record for Kisspeptin-10", "publisher": "U.S. Food and Drug Administration", "url": "https://precision.fda.gov/ginas/app/ui/substances/06b53a1a-3415-4d25-8d7c-0cedb1006eb7", "kind": "Reference", "year": 2026, "accessedAt": "2026-08-30" }, { "label": "Kisspeptin-10 and reproductive hormone release in healthy men", "publisher": "PubMed · Journal of Clinical Endocrinology and Metabolism", "url": "https://pubmed.ncbi.nlm.nih.gov/21632807/", "kind": "Human pharmacology", "year": 2011, "accessedAt": "2026-08-30" }, { "label": "Intermittent and continuous Kisspeptin-10 exposure in healthy men", "publisher": "PubMed · Journal of Clinical Endocrinology and Metabolism", "url": "https://pubmed.ncbi.nlm.nih.gov/42549827/", "kind": "Human pharmacology", "year": 2026, "accessedAt": "2026-08-30" }, { "label": "Direct human comparison of Kisspeptin-10 and Kisspeptin-54", "publisher": "PubMed · Journal of Clinical Endocrinology and Metabolism", "url": "https://pubmed.ncbi.nlm.nih.gov/26089302/", "kind": "Human pharmacology", "year": 2015, "accessedAt": "2026-08-30" }, { "label": "2026 Prohibited List", "publisher": "World Anti-Doping Agency", "url": "https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf", "kind": "Anti-doping", "year": 2026, "accessedAt": "2026-08-30" } ] } }